PMID- 35749398
OWN - NLM
STAT- MEDLINE
DCOM- 20220803
LR  - 20220818
IS  - 1473-6586 (Electronic)
IS  - 0963-0643 (Linking)
VI  - 32
IP  - 5
DP  - 2022 Sep 1
TI  - Device-assisted intravesical chemotherapy treatment for nonmuscle invasive 
      bladder cancer: 2022 update.
PG  - 575-583
LID - 10.1097/MOU.0000000000001010 [doi]
AB  - PURPOSE OF REVIEW: To critically analyze the oncological outcomes and safety 
      profile of device-assisted intravesical chemotherapy studies reported in 2021. 
      Studies were considered eligible if they included patients with nonmuscle 
      invasive blood cancer (NMIBC), had a prospective or retrospective design, 
      included at least 10 patients, were published in 2021, and assessed the 
      oncological impact of device-assisted intravesical chemotherapy and/or reported 
      standardized adverse effects (AEs). RECENT FINDINGS: Eight new studies reported 
      oncological outcomes after hyperthermic intravesical chemotherapy (HIVEC). In 
      Bacillus Calmette-Guerin (BCG) naive patients, the reported 2-yr. recurrence-free 
      survival (RFS) ranged from 70.7% to 82.4%, with one study reporting 2 yr. 
      progression free survival (PFS) of 92%. In both BCG naive and BCG refractory 
      patients, the reported 1-yr. RFS ranged from 60.5% to 70% and PFS was 94% in one 
      study. For radiofrequency-induced HIVEC, the reported 5-yr. estimates were 38%for 
      RFS and 91.5%for PFS. Regarding AEs, 10.2% of patients had severe AEs. Six 
      studies reported AEs after HIVEC; the majorities were grade 1-2 AEs. SUMMARY: 
      Data coming from the studies published in the last years provides support for a 
      consolidating role of device-assisted intravesical chemotherapy as a safe and 
      effective alternative first- or second-line adjuvant treatment of patients with 
      NMIBC.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Vartolomei, Mihai Dorin
AU  - Vartolomei MD
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna, Austria.
AD  - Doctoral School, George Emil Palade University of Medicine, Pharmacy, Science and 
      Technology from TarguMures, Targu Mures, Romania.
FAU - Ferro, Matteo
AU  - Ferro M
AD  - Urology Department, European Institute of Oncology, Milan, Italy.
FAU - Roth, Beat
AU  - Roth B
AD  - Department of Urology, Centre Hospitalier Universitaire Vaudois (CHUV), 
      University of Lausanne, Lausanne, Switzerland.
FAU - Teoh, Jeremy Yuen-Chun
AU  - Teoh JY
AD  - S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong 
      Kong, Hong Kong, China.
FAU - Gontero, Paolo
AU  - Gontero P
AD  - Division of Urology, Citta Della Salute e Della Scienza di Torino, Molinette 
      Hospital, University of Turin, Torino, Italy.
FAU - Shariat, Shahrokh F
AU  - Shariat SF
AD  - Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 
      Vienna, Austria.
AD  - Departments of Urology, Weill Cornell Medical College, New York, New York.
AD  - Department of Urology, University of Texas Southwestern, Dallas, Texas, USA.
AD  - Department of Urology, Second Faculty of Medicine, Charles University, Prag, 
      Czech Republic.
AD  - Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State 
      Medical University, Moscow, Russia.
AD  - Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, 
      Amman, Jordan.
AD  - Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220624
PL  - United States
TA  - Curr Opin Urol
JT  - Current opinion in urology
JID - 9200621
RN  - 0 (BCG Vaccine)
SB  - IM
MH  - Administration, Intravesical
MH  - BCG Vaccine
MH  - Humans
MH  - Neoplasm Invasiveness
MH  - Neoplasm Recurrence, Local
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - *Urinary Bladder Neoplasms/drug therapy
EDAT- 2022/06/25 06:00
MHDA- 2022/08/04 06:00
CRDT- 2022/06/24 13:43
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/08/04 06:00 [medline]
PHST- 2022/06/24 13:43 [entrez]
AID - 00042307-202209000-00023 [pii]
AID - 10.1097/MOU.0000000000001010 [doi]
PST - ppublish
SO  - Curr Opin Urol. 2022 Sep 1;32(5):575-583. doi: 10.1097/MOU.0000000000001010. Epub 
      2022 Jun 24.